The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana
Open accessAbstract
BACKGROUND: A preliminary safety signal for neural-tube defects was previously reported in association with dolutegravir exposure from the time of conception, which has affected choices of antiretroviral treatment (ART) for human immunodeficiency virus (HIV)-infected women of reproductive potential. The signal can now be evaluated with data from follow-up of additional pregnancies. METHODS: We conducted birth-outcomes surveillance at hospitals throughout Botswana, expanding from 8 to 18 sites in 2018. Trained midwives performed surface examinations of all live-born and stillborn infants. Research assistants photographed abnormalities after maternal consent was obtained. The prevalence of neural-tube defects and major external structural defects according to maternal HIV infection and ART exposure status was determined. In the primary analyses, we used the Newcombe method to evaluate differences in prevalence with 95% confidence intervals. RESULTS: From August 2014 through March 2019, surveillance captured 119,477 deliveries; 119,033 (99.6%) had an infant surface examination that could be evaluated, and 98 neural-tube defects were identified (0.08% of deliveries). Among 1683 deliveries in which the mother was taking dolutegravir at conception, 5 neural-tube defects were found (0.30% of deliveries); the defects included two instances of myelomeningocele, one of anencephaly, one of encephalocele, and one of iniencephaly. In comparison, 15 neural-tube defects were found among 14,792 deliveries (0.10%) in which the mother was taking any non-dolutegravir ART at conception, 3 among 7959 (0.04%) in which the mother was taking efavirenz at conception, 1 among 3840 (0.03%) in which the mother started dolutegravir treatment during pregnancy, and 70 among 89,372 (0.08%) in HIV-uninfected mothers. The prevalence of neural-tube defects was higher in association with dolutegravir treatment at conception than with non-dolutegravir ART at conception (difference, 0.20 percentage points; 95% confidence interval [CI], 0.01 to 0.59) or with other types of ART exposure. Major external structural defects were found in 0.95% of deliveries among women exposed to dolutegravir at conception and 0.68% of those among women exposed to non-dolutegravir ART at conception (difference, 0.27 percentage points; 95% CI, -0.13 to 0.87). CONCLUSIONS: The prevalence of neural-tube defects was slightly higher in association with dolutegravir exposure at conception than with other types of ART exposure at conception (3 per 1000 deliveries vs. 1 per 1000 deliveries). (Funded by the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions
Agresti, A., & Coull, B. A. (1998) · The American Statistician · doi:10.1080/00031305.1998.10480550 · Cited by 3,223
Villar, J., Ismail, L. C., Victora, C. G., Ohuma, E. O., Bertino, E., Altman, D. G., Lambert, A., Papageorghiou, A. T., Carvalho, M., Jaffer, Y. A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60932-6 · Cited by 2,281
Interval estimation for the difference between independent proportions: comparison of eleven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i · Cited by 1,851
Easy SAS Calculations for Risk or Prevalence Ratios and Differences
Spiegelman, D. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi188 · Cited by 1,738
Botto, L. D., Moore, C. A., Khoury, M. J., & Erickson, J. D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911113412006 · Cited by 980
Approximate Is Better than "Exact" for Interval Estimation of Binomial Proportions
Agresti, A., & Coull, B. A. (1998) · The American Statistician · doi:10.2307/2685469 · Cited by 972
Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception
Zash, R., Makhema, J., & Shapiro, R. L. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1807653 · Cited by 378
Self-citationDecline in the Prevalence of Spina Bifida and Anencephaly by Race/Ethnicity: 1995–2002
Williams, L. J., Rasmussen, S. A., Flores, A., Kirby, R. S., & Edmonds, L. D. (2005) · Pediatrics · doi:10.1542/peds.2005-0592 · Cited by 320
INTERGROWTH-21st very preterm size at birth reference charts
Villar, J., Giuliani, F., Fenton, T. R., Ohuma, E. O., Ismail, L. C., & Kennedy, S. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00384-6 · Cited by 311
Ford, N., Mofenson, L., Shubber, Z., Calmy, A., Andrieux-Meyer, I., Vitoria, M., Shaffer, N., & Renaud, F. (2014) · AIDS · doi:10.1097/qad.0000000000000231 · Cited by 275
Population impact of preterm birth and low birth weight on developmental disabilities in US children
Schieve, L. A., Tian, L. H., Rankin, K., Kogan, M. D., Yeargin-Allsopp, M., Visser, S., & Rosenberg, D. (2016) · Annals of Epidemiology · doi:10.1016/j.annepidem.2016.02.012 · Cited by 211
Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy
Zash, R., Jacobson, D. L., Diseko, M., Mayondi, G., Mmalane, M., Essex, M., Petlo, C., Lockman, S., Makhema, J., & Shapiro, R. L. (2017) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2017.2222 · Cited by 181
Self-citationMyelomeningocele in a child with intrauterine exposure to efavirenz
Fundaro, C., Genovese, O., Rendeli, C., Tamburrini, E., & Salvaggio, E. (2002) · AIDS · doi:10.1097/00002030-200201250-00025 · Cited by 160
Zash, R., Jacobson, D. L., Diseko, M., Mayondi, G. K., Mmalane, M. O., Essex, M., Gaolethe, T., Petlo, C., Lockman, S., Holmes, L. B., et al. (2018) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30218-3 · Cited by 152
Self-citationPericonceptional Exposure to Efavirenz and Neural Tube Defects
Santis, M. D., Carducci, B., Santis, L. D., Cavaliere, A. F., & Straface, G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.3.355 · Cited by 140
Vitória, M., Hill, A. M., Ford, N. P., Doherty, M. C., Clayden, P., Venter, F., Ripin, D. H. B., Flexner, C. W., & Domanico, P. L. (2018) · AIDS · doi:10.1097/qad.0000000000001845 · Cited by 133
Phillips, A. N., Venter, F., Havlir, D. V., Pozniak, A., Kuritzkes, D. R., Wensing, A. M. J., Lundgren, J. D., Luca, A. D., Pillay, D., Mellors, J. W., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30317-5 · Cited by 129
Accuracy Loss Due to Selection Bias in Cohort Studies with Left Truncation
Schisterman, E. F., Cole, S. R., Ye, A., & Platt, R. W. (2013) · Paediatric and Perinatal Epidemiology · doi:10.1111/ppe.12073 · Cited by 122
Conditions for Bias from Differential Left Truncation
Howards, P. P., Hertz‐Picciotto, I., & Poole, C. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwk027 · Cited by 121
Cognitive and Behavioral Outcomes of Intrauterine Growth Restriction School-Age Children
Chen, J., Chen, P., Bo, T., & Luo, K. (2016) · PEDIATRICS · doi:10.1542/peds.2015-3868 · Cited by 61
Left Truncation Bias as a Potential Explanation for the Protective Effect of Smoking on Preeclampsia
Lisonkova, S., & Joseph, K. S. (2015) · Epidemiology · doi:10.1097/ede.0000000000000268 · Cited by 44
Zash, R., Williams, P. L., Sibiude, J., Lyall, H., & Kakkar, F. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1226281 · Cited by 31
Self-citationDolutegravir in pregnancy—effects on HIV-positive women and their infants
Bornhede, R., Soeria-Atmadja, S. D., Westling, K., Pettersson, K., & Navér, L. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3195-9 · Cited by 22
HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK
(2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25187 · Cited by 20
Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
Chouchana, L., Beeker, N., & Tréluyer, J. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002065 · Cited by 19
Cited by
Saag, M. S., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Thompson, M. A., Sax, P. E., Smith, D. M., Benson, C. A., Buchbinder, S. P., del Rio, C., et al. (2020) · JAMA · doi:10.1001/jama.2020.17025 · Cited by 471
Venter, W. D. F., Sokhela, S., Simmons, B., Moorhouse, M., Fairlie, L., Mashabane, N., Serenata, C., Akpomiemie, G., Masenya, M., Qavi, A., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30241-1 · Cited by 269
Thompson, M. A., Horberg, M. A., Agwu, A. L., Colasanti, J. A., Jain, M. K., Short, W. R., Singh, T., & Aberg, J. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1391 · Cited by 256
Garcia, L. P., Van de Wijer, L., Hanswijk, S. I., Rando, J., Witteveen, J. S., Middelman, A., ter Heine, R., de Mast, Q., Martens, G. J. M., van der Ven, A. J. A. M., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114050 · Cited by 6
Metadata
- Authors
- Zash, R., Holmes, L., Diseko, M., Jacobson, D. L., Brummel, S., Mayondi, G., Isaacson, A., Davey, S., Mabuta, J., Mmalane, M., Gaolathe, T., Essex, M., Lockman, S., Makhema, J., & Shapiro, R. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-08-29
- Volume
- 381
- Issue
- 9
- Pages
- 827-840
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2963164305
- Cited by
- 387
- References
- 25
- FWCI
- 40.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.